Form 4: RenovoRx Executive Leesa Gentry Acquires 190,000 Incentive Stock Options

Chief Clinical Officer Leesa Gentry acquired 190,000 incentive stock options in RenovoRx, Inc. on March 6, 2024.

Summary

• On March 6, 2024, Leesa Gentry, Chief Clinical Officer of RenovoRx, Inc., acquired 190,000 incentive stock options.
• The options have an exercise price of $1.69.
• These options vest over four years, at a rate of 1/48 per month, starting March 1, 2024.
• The options are granted under the company's 2021 Omnibus Equity Incentive Plan.
• Gentry directly owns these derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to an executive. It doesn't inherently indicate positive or negative news, but rather a standard part of executive compensation.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for executives to receive stock options as part of their compensation package.

Stakeholder Impact

• The granting of stock options aligns the executive's interests with those of the shareholders, potentially incentivizing them to increase shareholder value.

Key Dates